P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(17 sites)
United States
University of California San Diego, La Jolla, California Loma Linda University Cancer Center, Loma Linda, California Cedars-Sinai Medical Center, Los Angeles, California Advent Health Orlando, Orlando, Florida Indiana University, Indianapolis, Indiana Our Lady of the Lake Hospital, Baton Rouge, Louisiana Ochsner Clinic Foundation, New Orleans, Louisiana Wayne State - Karmanos Cancer Institute, Detroit, Michigan NYU Grossman School of Medicine, New York, New York UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina University of Cincinnati, Cincinnati, Ohio University of Oklahoma, Health Sciences Center, Oklahoma City, Oklahoma Oregon Health & Science University, Portland, Oregon Pennsylvania State University, Hershey, Pennsylvania Prisma Health - Upstate Cancer Institute, Greenville, South Carolina Vanderbilt University Medical Center, Nashville, Tennessee Baylor Scott & White Research Institute, Dallas, Texas Last updated February 2026